Lytix Biopharma AS
OSE:LYTIX
Lytix Biopharma AS
Total Other Income
Lytix Biopharma AS
Total Other Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Other Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
Lytix Biopharma AS
OSE:LYTIX
|
Total Other Income
-kr1k
|
CAGR 3-Years
86%
|
CAGR 5-Years
71%
|
CAGR 10-Years
N/A
|
|
|
Hofseth Biocare ASA
OSE:HBC
|
Total Other Income
-kr1k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
68%
|
CAGR 10-Years
55%
|
|
|
B
|
Bergenbio ASA
OSE:BGBIO
|
Total Other Income
-kr1k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Arcticzymes Technologies ASA
OSE:AZT
|
Total Other Income
-kr1k
|
CAGR 3-Years
84%
|
CAGR 5-Years
70%
|
CAGR 10-Years
N/A
|
|
|
N
|
Nykode Therapeutics ASA
OSE:NYKD
|
Total Other Income
-$1.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
T
|
Thor Medical ASA
OSE:TRMED
|
Total Other Income
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Lytix Biopharma AS
Glance View
Lytix Biopharma AS develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as oncology treatments. The company is headquartered in Oslo, Oslo. The company went IPO on 2021-06-14. The firm's product, LTX-315, is a oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The firm serves customers domestically.
See Also
What is Lytix Biopharma AS's Total Other Income?
Total Other Income
-1k
NOK
Based on the financial report for Dec 31, 2023, Lytix Biopharma AS's Total Other Income amounts to -1k NOK.
What is Lytix Biopharma AS's Total Other Income growth rate?
Total Other Income CAGR 5Y
71%
Over the last year, the Total Other Income growth was 99%. The average annual Total Other Income growth rates for Lytix Biopharma AS have been 86% over the past three years , 71% over the past five years .
You don't have any saved screeners yet